Clinical Trials Logo

Chronic Disease clinical trials

View clinical trials related to Chronic Disease.

Filter by:

NCT ID: NCT00380536 Completed - Chronic Disease Clinical Trials

Medical Self-Management for Improving Health Behavior Among Individuals in Community Mental Health Settings

Start date: September 2006
Phase: N/A
Study type: Interventional

This study will evaluate the effectiveness of a medical illness self-management program in improving the health and health behavior of people who are receiving care at a community mental health center.

NCT ID: NCT00380133 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive Pulmonary Disease) Patients

Start date: June 2005
Phase: Phase 1
Study type: Interventional

This study will assess the effects of single oral doses of SB681323 and prednisolone on biomarkers in induced sputum and blood COPD patients

NCT ID: NCT00379730 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: March 21, 2006
Phase: Phase 1
Study type: Interventional

Prednisolone will be used as a model medication to identify new clinical outcomes for future evaluation of new therapies in short-term studies (up to 4 weeks) in patients with Chronic Obstructive Pulmonary Disease (COPD).

NCT ID: NCT00376714 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Disease

Start date: August 16, 2006
Phase: Phase 2
Study type: Interventional

GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long duration of action of GSK233705 when administered via inhalation in animal models supports the potential for use as a once-daily bronchodilator for chronic obstructive pulmonary disease.

NCT ID: NCT00373932 Completed - COPD Clinical Trials

Real-Time Support for Exercise Persistence in COPD

Start date: May 2006
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this exploratory study is to determine the feasibility, acceptability, and efficacy of an exercise persistence intervention for patients with chronic obstructive pulmonary disease (COPD) following pulmonary rehabilitation (PR).

NCT ID: NCT00372112 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Start date: November 3, 2006
Phase: Phase 2
Study type: Interventional

The compound GW642444 has previously been found to be well tolerated with no significant side effects in subjects with asthma and healthy volunteers. This study will assess the safety and tolerability of GW642444 in subjects with COPD in order to obtain information to support dosing in a broader population of subjects with COPD

NCT ID: NCT00364273 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

GSK159802 In Healthy Male Subjects And Asthmatics

Start date: August 24, 2005
Phase: Phase 1
Study type: Interventional

GSK159802 is a potent, inhaled, long acting selective beta-2-receptor agonist (LABA), which is being developed for once daily treatment of asthma and COPD as part of a combination product with a once daily inhaled corticosteroid and also as a standalone product for the treatment of COPD. Stimulation of the beta-2-agonist in the lung mainly relaxes bronchial smooth muscle cells which results in bronchodilation. Unwanted systemic side effects related with beta-2-agonist treatment such as tachycardia, tremor, hyperglycemia and hypokalemia are limited by local administration and also tend to show tachyphylaxis. The LABAs that are currently available (e.g., salmeterol, formoterol) require twice-daily administration, given their duration of action. Therefore, there is significant opportunity for a once-daily inhaled medication to improve patient compliance and overall disease management by providing sustained, 24-hour bronchodilation.

NCT ID: NCT00361959 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease

Start date: June 2003
Phase: Phase 4
Study type: Interventional

This is a comparator study to assess the relative efficacy of the combination product fluticasone propionate/salmeterol 50/500 and tiotropium bromide on the rate of exacerbations of chronic obstructive pulmonary disease (COPD) over a two year study interval.

NCT ID: NCT00359788 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.

Start date: July 2006
Phase: Phase 4
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotropium HandiHaler 18 micrograms (mcg) daily compared to Combivent Metered Dose Inhaler (MDI) Chlorofluorocarbon Inhalation Aerosol 2 actuations four times a day in Chronic Obstructive Pulmonary Disease (COPD) patients currently prescribed Combivent® MDI.

NCT ID: NCT00358488 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients

Start date: April 2006
Phase: Phase 2
Study type: Interventional

This study is designed to determine the efficacy and safety of a new long-acting beta-agonist for asthma patients (GSK159797) following dosing for 14 days.